Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2024-09-16 00:00:00 ET · period of report 2024-09-12 · accession 0000950170-24-106915 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-16 | 2024-09-12 | AMLX | Cohen Joshua B | Co-CEO, Dir | M - OptEx | $1.57 | +34.4K | 3.24M | +1% | +$54.1K |
| D | 2024-09-16 | 2024-09-12 | AMLX | Cohen Joshua B | Co-CEO, Dir | M - OptEx | $0.00 | -34.4K | 1,857 | -95% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-12 | M | A | 34,449 | $1.57 | 3,237,301 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-09-12 | M | D | 34,449 | $0.00 | 1,857 | D | $1.57 · — to 2025-02-26 | 34,449 Common Stock | (F1) This option is fully vested and exercisable. |